This Article Full Text Full Text (PDF) All Versions of this Article: 0192623309332995v1 0192623309332995v2 37/4/438    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Scopus Google Scholar Articles by Shimo, T. Articles by Nagata, O. PubMed PubMed Citation Articles by Shimo, T. Articles by Nagata, O. Social Bookmarking                         What's this?

FYX-051, a Xanthine Oxidoreductase Inhibitor, Induces Nephropathy in Rats, but not in Monkeys

Research Laboratories 2, Fuji Yakuhin Co., Ltd., Nishi-ku, Saitama, Japan

Correspondence: Takeo Shimo, Ph.D., Research Laboratories 2, Fuji Yakuhin Co., Ltd., 636-1 Iidashinden, Nishi-ku, Saitama 331-0068, Japan; e-mail:t-shimo{at}fujiyakuhin.co.jp.

The present studies were performed to investigate the possible mechanism of marked species differences on nephropathy found in the long-term toxicity study of FYX-051, a xanthine oxidoreductase inhibitor. In the twenty-six-week dose toxicity study in the rat, in which FYX-051 was administered by oral gavage at 0.04, 0.2, and 1 mg/kg, xanthine-mediated nephropathy was seen only at 1 mg/kg, despite the presence of xanthine crystals in urine at 0.2 mg/kg and more; however, in the fifty-two-week dose toxicity study in the monkey, in which FYX-051 was administered by oral gavage at 30, 100, and 300 mg/kg, no toxicities were seen, even at 300 mg/kg. These outcomes showed there would be 1500-fold or more differences in the mode of intrarenal xanthine deposition between rats and monkeys. Thus we performed the mechanistic study, and the following outcomes were obtained. First, the amount of urinary purine metabolites was thirty-fold higher in rats than in monkeys. Second, urinary xanthine solubility was sixfold higher in monkeys than in rats. Third, exposure levels of FYX-051 were five-fold higher in rats than in monkeys. Therefore, the present study indicated that the combined effects of purine metabolism, urinary xanthine solubility, and toxicokinetics would contribute to species differences in nephropathy, that is, absence of xanthine-mediated nephropathy in monkeys even at the highest dose of FYX-051.

Key Words: FYX-051 • xanthine oxidoreductase inhibitor • nephropathy • species differences • rats • monkeys

Abbreviations: MC, methylcellulose; • NOAEL, no-observed adverse effect level; • SD, standard deviation; • XOR, xanthine oxidoreductase.

This version was published on June 1, 2009

Toxicologic Pathology, Vol. 37, No. 4, 438-445 (2009)
DOI: 10.1177/0192623309332995


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?